Literature DB >> 18355301

Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK.

I Bone1, L Belton, A S Walker, J Darbyshire.   

Abstract

UNLABELLED: BACKGROUND, PURPOSE AND METHODS: This observational study assessed the effect of continuous intraventricular infusion of pentosan polysulphate (PPS) in seven patients at different clinical centres in the UK.
RESULTS: Complications of intraventricular catheterization were frequent. PPS was well-tolerated over a wide dose range (11-110 microg/kg/day) during the 6-month study. Four patients were assessed for the entire study period: one remained stable, two showed minimal deterioration and one progressed significantly.
CONCLUSION: Mean survival of all patients was longer than reported values for natural history of specific prion disorders. Possible reasons for these findings are explored.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18355301     DOI: 10.1111/j.1468-1331.2008.02108.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  24 in total

Review 1.  Sulfated glycosaminoglycans in protein aggregation diseases.

Authors:  Kazuchika Nishitsuji; Kenji Uchimura
Journal:  Glycoconj J       Date:  2017-04-11       Impact factor: 2.916

Review 2.  Rapidly progressive dementias and the treatment of human prion diseases.

Authors:  Brian S Appleby; Constantine G Lyketsos
Journal:  Expert Opin Pharmacother       Date:  2010-11-23       Impact factor: 3.889

3.  PRION-1 scales analysis supports use of functional outcome measures in prion disease.

Authors:  S Mead; M Ranopa; G S Gopalakrishnan; A G B Thompson; P Rudge; S Wroe; A Kennedy; F Hudson; A MacKay; J H Darbyshire; J Collinge; A S Walker
Journal:  Neurology       Date:  2011-10-19       Impact factor: 9.910

4.  Validation of Poly(Propylene Imine) Glycodendrimers Towards Their Anti-prion Conversion Efficiency.

Authors:  Matthias Schmitz; Niccolo Candelise; Eirini Kanata; Franc Llorens; Katrin Thüne; Anna Villar-Piqué; Susana Margarida da Silva Correia; Dimitra Dafou; Theodoros Sklaviadis; Dietmar Appelhans; Inga Zerr
Journal:  Mol Neurobiol       Date:  2019-12-17       Impact factor: 5.590

Review 5.  Developing Therapeutics for PrP Prion Diseases.

Authors:  Kurt Giles; Steven H Olson; Stanley B Prusiner
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

6.  Ethics in prion disease.

Authors:  Kendra Bechtel; Michael D Geschwind
Journal:  Prog Neurobiol       Date:  2013-07-29       Impact factor: 11.685

7.  Effect of transplantation of bone marrow-derived mesenchymal stem cells on mice infected with prions.

Authors:  Chang-Hyun Song; Osamu Honmou; Natsuo Ohsawa; Kiminori Nakamura; Hirofumi Hamada; Hidefumi Furuoka; Rie Hasebe; Motohiro Horiuchi
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

8.  Glycosaminoglycan sulphation affects the seeded misfolding of a mutant prion protein.

Authors:  Victoria A Lawson; Brooke Lumicisi; Jeremy Welton; Dorothy Machalek; Katrina Gouramanis; Helen M Klemm; James D Stewart; Colin L Masters; David E Hoke; Steven J Collins; Andrew F Hill
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

9.  Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survival.

Authors:  Abhisek Mukherjee; Diego Morales-Scheihing; Dennisse Gonzalez-Romero; Kristi Green; Giulio Taglialatela; Claudio Soto
Journal:  PLoS Pathog       Date:  2010-10-07       Impact factor: 6.823

10.  Management and prevention of human prion diseases.

Authors:  Silvia Graziano; Maurizio Pocchiari
Journal:  Curr Neurol Neurosci Rep       Date:  2009-11       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.